NCT00753896 trial results

Inclusion Criteria: * Have type 2 diabetes * At least 18 years of age at screening. * Have HbA1c of 7.1% to 10.0%, inclusive, at screening. * Have a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive. * Have been treated with a stable dose of TZD (≥4 mg/day rosiglitazone or ≥30 mg/day pioglitazone) for at least 120 days prior to Visit 1 OR Have been treated with a stable dose of TZD (≥4 mg/day rosiglitazone or ≥30 mg/day pioglitazone) for at least 120 days PLUS a stable dose of metformin for at least 90 days prior to Visit 1. * Have a history of stable body weight (not varying by \>10% for at least 3 months prior to screening). * If female of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopause) only. * Are not breastfeeding. * Test negative for pregnancy at the time of screening based on a serum pregnancy test. * Intend not to become pregnant during the study. * Have practiced a reliable method of birth control (e.g., use of oral contraceptives or approved hormonal implant; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for at least 6 weeks prior to screening. * Agree to continue to use a reliable method of birth control (see above) during the study. Exclusion Criteria: * Have had a clinically significant history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study, including myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, angioplasty. * Is expected to require coronary artery bypass surgery or angioplasty during the course of the study. * Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis * Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine ≥135 μmol/L for males and ≥110 μmol/L for females. * Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years. * Have known hemoglobinopathy or chronic anemia (hemoglobin concentration \<11.5 g/dL \[115 g/L\] for males, \<10.5 g/dL \[105 g/L\] for females). * Have clinically significant history or presence of severe gastrointestinal disease, particularly those which may impact gastric emptying, such as gastroparesis, pyloric stenosis, or gastric bypass surgery. * Have a history of pancreatitis. * Have had greater than three episodes of major hypoglycemia within 6 months prior to screening. * Have any contraindication for the OAD(s) which they use, according to local label requirements. * Are known to have active proliferative retinopathy. * Are receiving chronic (\>2 weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations)...